#International Research Awards on Oncology and Cancer Research

[spanishroyals]

September 21, 2023. London, United Kingdom.

Her Majesty Queen Letizia of Spain, honorary president of the Spanish Association Against Cancer (AECC) and it’s scientific foundation, visited Cancer Research UK today to commemorate the upcoming World Cancer Research Day. 

World Cancer Research Day is an initiative of the Spanish Association Against Cancer (AECC) and promotes the importance of cancer research and highlights how integral continued investment in research is to achieve the scientific advances we need to beat cancer.  

Her Majesty joined senior leaders from Cancer Research UK, the AECC, the Italian Foundation for Cancer Research (AIRC), and the European Society for Medical Oncology (ESMO) to recognise and celebrate international relationships in cancer research. 

Her Majesty’s visit included a meeting focussed on international researchers collaborating on co-funded research programmes and a panel discussion dedicated to the three key themes of this year’s World Cancer Research Day: integrating diversity, advancing research, and achieving equity. 

“Thank you so much for allowing me to be here today to see the successful teamwork between these organisations in this hard and complex journey of advancing in cancer research,” Her Majesty said.

Cancer Research UK’s partnership with AECC and AIRC began in 2016.  

Since then, they have worked together to co-fund the Accelerator Awards, which have helped to forge some strong relationships between leading institutions in the UK, Spain and Italy. 

Read more: https://news.cancerresearchuk.org/2023/09/21/queen-of-spain-visits-cancer-research-uk/

[mayank56]

Meet Dr. Rajkumar Mantri: Expert in Oral and Maxillofacial Surgery

Introduction

Meet Dr. Rajkumar Mantri, a highly skilled and recognized Oral and Maxillofacial Surgeon dedicated to providing exceptional dental care. His journey in the field of dentistry is both revealing and inspiring, marked by extensive education, hands-on training, and a passion for teaching. Let's unveil the essential aspects of his career and expertise.

Educational Background

Dr. Rajkumar Mantri's educational journey is impressive and comprehensive. Here are the key milestones:

2011: Earned BDS (Bachelor of Dental Surgery) degree from Modern Dental College and Research Center in Indore, MP.

2016: Completed Masters in Oral and Maxillofacial Surgery (MDS) from Darshan Dental College and Hospital in Udaipur, Rajasthan.

Additional Qualification: Holds a diploma in Immediate Functional Loading from Maharaja Vinayak Global University in Jaipur, Rajasthan.

Professional Expertise                                      

Recognized as an expert in his field, Dr. Rajkumar Mantri's professional credentials are remarkable:

IF Teacher and IF Master: Achieved in Immediate Loading from Munich, Germany, highlighting his expertise in advanced dental implantology techniques.

Director: Leads Kavyanjali Dental Clinic and Academy, and Kavyanjali Dental Material, employing proven strategies to deliver top-notch dental care and training.

Clinical Practice

Dr. Rajkumar Mantri's clinical practice spans multiple locations and extensive teaching:

Practices in Udaipur and Manasa, Neemuch Madhya Pradesh.

Conducted over 15 workshops focusing on implants and general dentistry.

Trained 10 BDS doctors at his academy, imparting essential tips and techniques to the next generation of dental professionals.

Special Interests

Dr. Rajkumar Mantri's special interests include Pterygoid Implants, particularly in their fixation and osseointegration of bone. His innovative approach ensures that his patients receive the ultimate care, with a clear focus on achieving the best possible outcomes.

Affiliations

Dr. Rajkumar Mantri is affiliated with several prestigious organizations:

Member of the Association of Oral and Maxillofacial Surgeons of India (AOMSI).

Member of the Indian Society of Oral Implantologists (ISOI).

Fellow and Member of the International Congress of Oral Implantologists (ICOI).

Masterclass Certification

On May 30th, 2022, Dr. Rajkumar Mantri completed the Masterclass in Immediate Loading. This certification, awarded by the International Implant Foundation in Munich, Germany, includes authorization to use Corticobasal® Implants and the Technology of the Strategic Implant®. This advanced training has further boosted his ability to provide cutting-edge dental implant solutions.

Additional Training and Certifications

Dr. Rajkumar Mantri's commitment to excellence is evident in his additional training and certifications:

March 1 - April 15, 2015: Rotation in the Surgical Oncology Department at The Gujarat Cancer and Research Institute, gaining valuable insights into oncology-related dental procedures during MDS.

September 10 - October 9, 2015: Fellow in Training at GS Memorial Plastic Surgery Hospital and Trauma Centre, where he observed and assisted in numerous cleft lip and palate surgeries, mastering the principles of cleft surgery, including examination, evaluation of defects, surgical planning, and postoperative care during MDS.

One-year Senior Residentship: Completed at RNT Medical College.

Senior Lecturer: Served at RR Dental College.

Conclusion

Dr. Rajkumar Mantri's commitment to excellence in dental care, coupled with his advanced training and extensive teaching experience, has made him a trusted name in Oral and Maxillofacial Surgery. At Kavyanjali Dental Clinic and Academy, you can expect comprehensive and cutting-edge treatment delivered with dedication and care. His expertise, combined with a clear and concise approach to patient care, ensures that every patient receives the ultimate dental experience.

For more information or to book an appointment, visit Kavyanjali Dental Clinic and Academy today.

Address: Talesara Residency, 13-14, A Rd, near J.K. Hospital, Bhupalpura, Bhopalpura, Udaipur, Rajasthan 313001 Phone: 7740859567

Dr. Rajkumar Mantri looks forward to helping you achieve optimal dental health and unveiling a brighter smile.

Check out Instagram: https://www.instagram.com/drrajkumarmantri?igsh=aWl6czhmeXJxeXVy

[wellnessweb]

Consumer Demand and Immunomodulators Market Size

The Immunomodulators Market size was USD 224.17 Billion in 2023 and is expected to Reach USD 368.23 Billion by 2031 and grow at a CAGR of 6.4% over the forecast period of 2024-2031.Immunomodulators market is experiencing rapid growth driven by the rising prevalence of autoimmune diseases, cancer, and infectious diseases. These agents, which include cytokines, monoclonal antibodies, and immune checkpoint inhibitors, modulate the immune system to enhance or suppress its response, offering new therapeutic avenues. Advances in biotechnology and a deeper understanding of immune mechanisms are spurring innovation, leading to the development of novel immunomodulatory drugs. Additionally, increased investments in research and development, coupled with favorable regulatory policies, are further propelling the market. The expanding use of these agents in personalized medicine underscores their potential to revolutionize treatment paradigms and improve patient outcomes globally.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3112

Market Scope & Overview

The market research report is an ideal source of information, and market studies are crucial for global businesses. In order to give a qualitative and quantitative evaluation of the development of the global economy, Immunomodulators Market  research examines a wide range of nations. The market research study analyses historical information and forecasts to estimate the size of the global market. The global business overview includes tables and figures with key industry statistics, market data and analysis for organizations and consumers.

Market Segmentation Analysis

By Product Type

Immunostimulants

Immunosuppressants

Other

By Application

Respiratory

Oncology

HIV

Other

By End Users

Clinics

Hospitals

Other

COVID-19 Pandemic Impact Analysis

The research goes into great depth about how these pandemics affected various regions of the world. The COVID-19 epidemic's global spread has had a significant influence on the Immunomodulators Market  in a number of ways. The report also offers advice on how market participants might continue to make money in such challenging circumstances.

Regional Outlook

The Immunomodulators Market  research report explains current developments in significant regional marketplaces and the various choices service providers throughout the world have. This research report covers all of Europe, North America, Latin America, Asia Pacific, and the rest of the world. A competitive market analysis ranks the top rivals based on corporate strengths and product offerings.

Competitive Analysis

The research examines the significance of the field, in addition to its many elements and anticipated repercussions. Discussions of expert perspectives, environmental facts, and marketing strategies are included. The Immunomodulators Market  research covers upstream sector differences, market segmentation, business environment, demand development, cost and pricing structure, and business climate.

Key Reasons to Purchase Immunomodulators Market  Report

The market report evaluates the findings of in-depth secondary research, primary interviews with subject matter experts, and internal expert interviews.

Financial analytics, fundamental data, regional engagement, sales effectiveness, product quality, and sector contribution are all used to rank the top businesses in the market.

Conclusion

The size of the market, the successful business practices of the major organizations, and the exposure of regional firms are some of the factors taken into account by Immunomodulators Market research. For the development of market-dominating methods, these insights are crucial.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Patient Portal Market Analysis

Plasma Therapy Market Analysis

Preeclampsia Diagnostics Market Analysis

Serum free Media Market Analysis

Glaucoma Therapeutics Market Analysis

[gastro-delhi]

Dr. Neeraj Goel: The Best Cancer Surgeon in Delhi

Dr. Neeraj Goel is known as the best Cancer Surgeon in Delhi. He’s really good at fixing cancer with surgery. People like him because he’s nice and knows a lot about cancer. He’s been helping people for a long time and has made many families happy. Dr. Goel is always learning new things to help his patients better. He doesn’t just do surgery; he also helps and supports his patients a lot. Everyone in Delhi thinks Dr. Neeraj Goel is the best at fixing cancer.

Dr. Neeraj Goel Cancer Surgeon / GI Oncology He is the first GI Surgeon in East Delhi adjoining NCR to start full-fledged GI Surgical Services at Pushpanjali Crosslay Hospital (now Max Hospital, Vaishali). Presently he is working as Clinical Lead Senior Consultant GI Oncology, GI and HPB Surgery at Dharamshila Narayana Superspeciality Hospital, Delhi.

Dr. Neeraj Goel MS, MCh, Sr. Consultant Cancer Surgeon GI Surgery Dr. Neeraj Goel is the first GI Surgeon in East Delhi adjoining NCR to provide comprehensive GI surgical and GI Oncologic care. He is trained in GI Surgery at coveted GB Pant Hospital. He is a renowned Cancer Surgeon in Delhi with an experience of more than 15 years, He has also done his fellowship in HPB Surgery from South Korea. He performs all kind of laparoscopic GI surgical procedures.

Cancer Surgeon in Delhi | GI Surgeon in Delhi | HIPEC Surgeon in Delhi | Colorectal Surgeon in Delhi

Dr Neeraj Goel is the first GI Surgeon in the East Delhi NCR to provide comprehensive Cancer and GI Oncologic care. He is trained in GI Surgery from coveted GB Pant Hospital. He is a renowned Cancer Surgeon in Delhi with an experience of more than 15 years, He has also done his fellowship in HPB Surgery from South Korea. performs all kind of laparoscopic GI surgical procedures.

Professional Qualifications Dr. Neeraj Goel started his medical professional journey from University College Medical Science. He did his post graduation (MS) from Hardinge Medical College. He has done his postdoctoral degree(MCh) in GI Surgery from GB Pant Hospital.

He is the first GI Surgeon In East Delhi adjoining NCR to start full-fledged GI Surgical Services At Pushpanjali Crosslay Hospital (Now Max Hospital). Presently he is working as Director Senior Consultant in Dharamshila Narayana Superspciality Hospital, Delhi. He is the only surgeon in East Delhi and NCR and amongst few in Country to perform complex surgery of Cytoreduction with HIPEC (Hyperthermic Introperitoneal Chemotherapy) for disseminated peritoneal Cancers. He is performing full array of advanced Minimal Access GI and HPB Surgery. He has worked as Senior Consultant Max Super specially Hospitals.

Minimal Access HPB Surgery He is a fellow of Minimal Access HPBS Surgery from Seoul National University Bundang Hospital, South Korea.

Robotic Surgery He is a certified Robotic Surgeon trained at International School of Robotic Surgery, Italy.

Advanced Laparoscopic Colorectal Surgery: Taiwan He is trained in Taiwan for the advanced laparoscopic Colorectal Surgeries.

Weight loss Central at University of Cincinnati - Ohio USA He has been to Weight Loss Centre at the University of Cincinnati, Ohio USA for Bariatric Surgery (Weight Loss Surgery).

GB Pant Hospital - Delhi He completed his postdoctoral degree (MCh) in Surgical Gastroenterology/GI Surgery from coveted GB Pant Hospital Delhi.

Rajiv Gandhi cancer institute Research Center - Delhi At Rajiv Gandhi institute, he was involved in management and research of abdominal cancer.

He has to his credit multiple Chapters in post graduate and graduate books. He has many publications in national and international journal.

Awards Honors Faculty at various National and State level Surgical Conferences Poster presentation on “Neuroendocrine Tumors of the ampulla” at Asia Pacific Hepatopancreatobiliary Association Conference in Shanghai, China.

Presented Poster on “Neuroendocrine Tumors of the ampulla” at Annual Conference of IASG, BaA video, India

Video presentation on ”Laparoscopic Lateral Pancreatojejunostomy” at Annual Conference of IASG, Bangaluru, India

Poster Presentation on “Isolated extrahepatic bile duct injury after blunt trauma abdomen” at Annual Conference of IASG, Bhopal, India

Stood Second In the Surgery Quiz at the Annual Conference of Delhi State Chapter of ASI, (as a team event).

Presented following papers at the Annual Meeting of Oncology Group of Delhi (OGD).

Gastrointestinal Stromal Tumors and Imatinib and its effect on Blood Sugar control. Deltopectoral Flap for Head Neck Malignancies.

Presented Paper on Gastrointestinal Stromal Tumors: Our Experience at Annual Conference of Delhi State Chapter Of ASI.

Presented following Papers at Annual Conference of Delhi State Chapter of ASI Postmastectomy Edema - An added a venous component Small Bowel Tumors. Biliary Fistula of unknown origin - An iatrogenic Complication. Rare skin Tumors.

To schedule an appointment With Dr. Neeraj Goel for Cancer Surgeon in Delhi, please contact: Name: Dr. Neeraj Goel (Cancer Surgeon in Delhi) Address: D-1, Hakikat Rai Rd, Block D, Adarsh Nagar, Delhi, 110033 Phone: +91–9667365169, +91–9599294453 Website: www.gastrodelhi.com

[saumayatripathi]

Unveiling the Innovations: Leading Anticancer Drug Manufacturers in India

In the landscape of anticancer drug manufacturing in India, stands as a leading player, housing a cluster of innovative companies that are revolutionizing the fight against cancer. Among these pioneering manufacturers, Florencia Healthcare has emerged as a prominent name, contributing significantly to this global battle. With a commitment to excellence and a strong focus on technology-driven research and development, Florencia Healthcare has been instrumental in equipping healthcare professionals with a diverse range of anticancer drugs that adhere to international quality standards.

Florencia Healthcare's dedication to patient-centric care and its continuous quest for breakthrough solutions have earned it a reputation as a trusted partner in the oncology community. By harnessing the power of advanced technologies and strategic collaborations, Florencia Healthcare is shaping the future of anticancer drug manufacturing in India, ultimately driving positive patient outcomes across the globe. As a leading pioneer in the field, Florencia Healthcare embraces innovation, compassion, and a relentless pursuit of medical advancements, ensuring that individuals affected by cancer receive the best possible care.

Importance of Anticancer Drug Manufacturers in India

India, with its vast population and rising cancer incidence, has a critical need for high-quality, affordable anticancer drugs. The country's pharmaceutical industry plays a pivotal role in meeting this demand and improving patient outcomes. Anticancer drug manufacturers in India contribute significantly to global healthcare by providing access to life-saving medications at competitive prices. These manufacturers not only cater to the domestic market but also export their products to various countries, thereby contributing to the global fight against cancer.

Overview of the Indian Pharmaceutical Industry

The Indian pharmaceutical industry is one of the largest and fastest-growing sectors in the country. Known for its cost-effective generic drugs, India has become a global hub for pharmaceutical manufacturing. The industry encompasses a wide range of companies, from small-scale manufacturers to large multinational corporations. With a robust regulatory framework and a strong emphasis on research and development, the Indian pharmaceutical industry has gained recognition for its quality standards and technological advancements.

Leading Anticancer Drug Manufacturers in India

Several pharmaceutical companies in India have made significant contributions to the field of anticancer drug manufacturing. These companies possess state-of-the-art infrastructure, cutting-edge research facilities, and a team of highly skilled scientists and healthcare professionals. Alongside Florencia Healthcare, other leading manufacturers in India include:

Florencia Healthcare- Commitment to excellence has been recognized through various industry awards and accolades, further solidifying its position as a leading manufacturer in the Indian pharmaceutical landscape.

Biocon Limited - A pioneer in biotechnology-based anticancer drugs, Biocon is known for its innovative therapies and commitment to affordability.

Dr. Reddy's Laboratories - With a strong global presence, Dr. Reddy's Laboratories specializes in developing and manufacturing a wide range of generic anticancer medications.

Sun Pharmaceutical Industries - Sun Pharma focuses on research and development of novel drug delivery systems and has a diverse portfolio of anticancer drugs.

Cipla Limited - Cipla has been at the forefront of providing affordable cancer treatments, making a significant impact on the accessibility of anticancer drugs in India and beyond.

History and Achievements of Florencia Healthcare

Florencia Healthcare, founded in 2011, has a rich history of pioneering research and development in the field of anticancer drugs. The company has consistently strived to deliver superior-quality medications that meet the highest international standards. Florencia Healthcare's commitment to excellence has been recognized through various industry awards and accolades, further solidifying its position as a leading manufacturer in the Indian pharmaceutical landscape.

Innovative Approaches in Anticancer Drug Manufacturing

Innovation is the cornerstone of the success of Florencia Healthcare and other leading oncology drug manufacturers and suppliers in India. These companies invest heavily in research and development to develop novel therapies, improve drug delivery systems, and enhance treatment outcomes. By leveraging advanced technologies such as artificial intelligence, machine learning, and genomics, these manufacturers can identify new drug targets, optimize drug formulations, and personalize treatment approaches for cancer patients.

Quality Standards and Certifications in the Pharmaceutical Industry

Maintaining stringent quality standards is of paramount importance in the pharmaceutical industry, especially when it comes to manufacturing anticancer drugs. Leading manufacturers like Florencia Healthcare adhere to internationally recognized quality management systems and certifications. These certifications, such as ISO 9001:2008, and Good Manufacturing Practice (GMP), ensure that the manufacturing processes are robust, efficient, and compliant with regulatory requirements. By adhering to these standards, manufacturers can guarantee the safety, efficacy, and reliability of their anticancer drugs.

The Role of Government Regulations in Drug Manufacturing

The Indian pharmaceutical industry operates under the guidance of various government regulations and regulatory bodies. The Central Drugs Standard Control Organization (CDSCO) is responsible for approving and monitoring the manufacturing, marketing, and distribution of drugs in India. These regulations ensure that the anticancer drugs produced by manufacturers like Florencia Healthcare meet the highest standards of safety, efficacy, and quality. Government support and favorable policies also play a crucial role in fostering innovation and enabling manufacturers to bring affordable anticancer drugs to market.

Challenges and Future Prospects for Anticancer Drug Manufacturers in India

While the Indian pharmaceutical industry has made significant strides in anticancer drug manufacturing, it faces several challenges. These include the increasing complexity of cancer therapies, rising research and development costs, and the need for continuous innovation. Additionally, the industry must navigate complex regulatory pathways and address the affordability and accessibility of anticancer drugs for all segments of society. However, with a strong focus on research, development, and strategic collaborations, manufacturers like Florencia Healthcare are well-positioned to overcome these challenges and drive the future of anticancer drug manufacturing in India.

Conclusion and the Impact of Florencia Healthcare on the Indian Pharmaceutical Industry

Florencia Healthcare, along with other leading anticancer drug manufacturers and exporters in India, has played a crucial role in shaping the landscape of cancer treatment. Through their commitment to innovation, adherence to quality standards, and patient-centric approach, these manufacturers have made a significant impact on the lives of cancer patients in India and around the world. Florencia Healthcare's dedication to excellence and continuous pursuit of breakthrough solutions position it as a trusted partner in the fight against cancer. As the Indian pharmaceutical industry continues to evolve, the contributions of manufacturers like Florencia Healthcare will undoubtedly drive positive change and transform the future of anticancer drug manufacturing.

Frequently Asked Questions (FAQs)

1. What role do anticancer drug manufacturers in India play in the global fight against cancer?

Anticancer drug manufacturers in India contribute significantly to global healthcare by providing access to high-quality and affordable medications. They cater to the domestic market and also export their products to various countries, thereby aiding the global fight against cancer.

2. What are some leading anticancer drug manufacturers in India apart from Florencia Healthcare?

Apart from Florencia Healthcare, other leading anticancer drug manufacturers in India include Biocon Limited, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla Limited. These companies are known for their innovative therapies, commitment to affordability, and global presence.

3. What are some of the innovative approaches employed by Indian anticancer drug manufacturers in drug manufacturing?

Indian anticancer drug manufacturers employ innovative approaches such as advanced technologies like artificial intelligence, machine learning, and genomics. These technologies help in identifying new drug targets, optimizing drug formulations, and personalizing treatment approaches for cancer patients.

4. How do anticancer drug manufacturers ensure the quality and safety of their medications?

Leading manufacturers adhere to internationally recognized quality management systems and certifications such as ISO 9001, ISO 13485, and Good Manufacturing Practice (GMP). These certifications ensure that manufacturing processes are robust, efficient, and compliant with regulatory requirements, guaranteeing the safety, efficacy, and reliability of anticancer drugs.

5. What are some challenges faced by anticancer drug manufacturers in India, and how are they addressing them?

Challenges faced by anticancer drug manufacturers in India include the increasing complexity of cancer therapies, rising research and development costs, and the need for continuous innovation. To address these challenges, manufacturers focus on research, development, and strategic collaborations to drive positive change and transform the future of anticancer drug manufacturing.

6. How do government regulations influence drug manufacturing in India?

The Indian pharmaceutical industry operates under the guidance of various government regulations and regulatory bodies, such as the Central Drugs Standard Control Organization (CDSCO). These regulations ensure that drugs, including anticancer medications, meet the highest standards of safety, efficacy, and quality. Government support and favorable policies also foster innovation and enable manufacturers to bring affordable drugs to market.

7. What impact has Florencia Healthcare had on the Indian pharmaceutical industry?

Florencia Healthcare, along with other leading anticancer drug manufacturers in India, has played a crucial role in shaping the landscape of cancer treatment. Through their commitment to innovation, adherence to quality standards, and patient-centric approach, these manufacturers have made a significant impact on the lives of cancer patients in India and around the world. Florencia Healthcare's dedication to excellence and continuous pursuit of breakthrough solutions position it as a trusted partner in the fight against cancer.

[otiskeene]

ICPO Foundation And SBMN Enter Strategic Partnership To Promote International Education Standards And Training Support In Brazil

A partnership to promote radiomolecular precision oncology (RPO) in Brazil has been announced by the Brazilian Society of Nuclear Medicine (SBMN) and the International Centers for Precision Oncology (ICPO) Foundation. By establishing ICPO Centers and deploying the ICPO Academy for Theranostics in Brazil, this collaboration hopes to progress the field internationally.

Together, ICPO and SBMN will transform RPO in Brazil with an emphasis on improving patient care, research, and education. Priority candidate hospital identification and the provision of Portuguese content for the ICPO Academy will be the main objectives of the first phase. across later stages, SBMN will advertise the Academy and provide hands-on training sessions across Brazil.

The partnership seeks to improve standards of best practices, promote precision oncology research and development, and provide access to efficient cancer treatments. SBMN will manage quality control and advance the Academy's visibility in Brazil, while ICPO will create the Academy's content and platform.

SBMN will also promote ICPO grants and awards among its members and create content for ICPO Community events. The collaboration seeks to enhance patient outcomes both domestically and internationally, standardize clinical procedures, and empower medical personnel.

SBMN President Dr. Rafael Lopes was enthusiastic about the partnership, saying it will improve patient care and advance therapeutic nuclear medicine. The collaboration supports ICPO's objective to enable its Centers through a highly inclusive Community and expand patient access to molecularly targeted precision oncology on a worldwide scale.

In conclusion, the partnership between SBMN and the ICPO Foundation represents a major advancement for radiomolecular precision oncology in Brazil and has the potential to improve the lives of cancer patients everywhere.

Read More - bit.ly/3OPpEGU

[curenishant]

Dr. Ashok Kumar Vaid | Best Oncologist in India

Dr. Ashok Kumar Vaid stands as a beacon of excellence in the field of oncology at Medanta Gurgaon, where he has garnered a reputation as the go-to expert for the treatment of organ-specific cancers, leukemias, and lymphomas. With a distinguished career spanning several decades, Dr. Vaid's journey to becoming one of India's leading oncologists is marked by remarkable achievements and contributions to the medical field.

Educational Background and Training

Dr. Vaid's academic journey commenced with an MBBS degree from Jammu University in 1984, laying the foundation for his illustrious career in medicine. He further honed his expertise by completing DNB in internal medicine and DM Medical Oncology in 1993. During his senior residency at Govt. Medical College, Jammu, from 1987 to 1989, he gained invaluable experience that would shape his future endeavors in oncology.

Professional Experience and Accolades

Prior to joining Medanta Gurgaon, Dr. Vaid served as the Head of the Department of Medical Oncology at Artemis Health Institute, Gurgaon, where he made significant strides in advancing cancer treatment. His exemplary contributions to the field of medicine were recognized with the prestigious Padma Shri award in 2009, a testament to his dedication and expertise.

Membership and Contributions

Dr. Vaid's commitment to advancing oncology extends beyond his clinical practice. He is actively involved in various prestigious organizations, including the Breast Cancer Foundation of India, Indian Society of Medical & Pediatric Oncology, and Indian Association of Gynaec Oncologists, among others. As a founder member of the Indian Cooperative Oncology Network (ICON), he has played a pivotal role in shaping the landscape of oncology research and treatment in India.

Pioneering Achievements

Dr. Vaid's pioneering spirit is evident in his groundbreaking work in bone marrow transplantation. He holds the unique distinction of having conducted the first 25 bone marrow transplants in any private sector hospital in North India, underscoring his commitment to pushing the boundaries of medical innovation.

Research and Publications

Dr. Vaid's contributions to oncology research are extensive, with numerous papers and clinical research published in prestigious national and international medical journals. His work has not only enriched the scientific community but has also had a profound impact on cancer treatment protocols both within India and globally.

Legacy of Excellence

Dr. Ashok Kumar Vaid's legacy as a trailblazer in oncology continues to inspire generations of medical professionals. His unwavering dedication to patient care, coupled with his relentless pursuit of medical advancement, cements his status as one of the finest oncologists in the country. Under his leadership, Medanta Gurgaon remains at the forefront of cancer treatment, providing hope and healing to countless patients battling this formidable disease.

[marketinsight1234]

Formulation Development Outsourcing Market: Global Industry Analysis and Forecast 2023 – 2030

Global Formulation Development Outsourcing Market was valued at USD 20.15 Billion in 2021 and is expected to reach USD 33.08 Billion by the year 2028, at a CAGR of 7.34%.

The increasing trend of major drugs' patent protection expiration and the rising number of pharmaceutical and biopharmaceutical companies that are outsourcing their services are expected to fuel the growth of the formulation development outsourcing market, worldwide. For instance, Cancer Research UK has initiatives to promote small molecule drug discovery. It runs a program known as the "Small Molecule Drug Discovery Project Award" and invests in milestone-driven projects at all stages of drug discovery, from target identification/validation to early preclinical studies.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

https://introspectivemarketresearch.com/request/15847

The latest research on the Formulation Development Outsourcing market provides a comprehensive overview of the market for the years 2023 to 2030. It gives a comprehensive picture of the global Formulation Development Outsourcing industry, considering all significant industry trends, market dynamics, competitive landscape, and market analysis tools such as Porter's five forces analysis, Industry Value chain analysis, and PESTEL analysis of the Formulation Development Outsourcing market. Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years. The report is designed to help readers find information and make decisions that will help them grow their businesses. The study is written with a specific goal in mind: to give business insights and consultancy to help customers make smart business decisions and achieve long-term success in their particular market areas.

Leading players involved in the Formulation Development Outsourcing Market include:

Charles River Laboratories International Inc., Aizant Drug Research Solutions Pvt Limited, Catalent Inc., Laboratory Corporation of America Holdings, Biocon Limited (Syngene International), PCI Pharma Services, Hermes Pharma, Pyramid Laboratories Inc and  other Major players. 

If You Have Any Query Formulation Development Outsourcing Market Report, Visit:

https://introspectivemarketresearch.com/inquiry/15847

Segmentation of Formulation Development Outsourcing Market:

By Service

Pre-Formulation Services

Formulation Optimization

By Application

Oncology

Genetic Disorders

Neurology

Infectious Diseases

Respiratory

Cardiovascular

Others

By Dosage Form          

Injectable

Oral

Topical

Other

By Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

What to Expect in Our Report?

(1) A complete section of the Formulation Development Outsourcing market report is dedicated for market dynamics, which include influence factors, market drivers, challenges, opportunities, and trends.

(2) Another broad section of the research study is reserved for regional analysis of the Formulation Development Outsourcing market where important regions and countries are assessed for their growth potential, consumption, market share, and other vital factors indicating their market growth.

(3) Players can use the competitive analysis provided in the report to build new strategies or fine-tune their existing ones to rise above market challenges and increase their share of the Formulation Development Outsourcing market.

(4) The report also discusses competitive situation and trends and sheds light on company expansions and merger and acquisition taking place in the Formulation Development Outsourcing market. Moreover, it brings to light the market concentration rate and market shares of top three and five players.

(5) Readers are provided with findings and conclusion of the research study provided in the Formulation Development Outsourcing Market report.

Our study encompasses major growth determinants and drivers, along with extensive segmentation areas. Through in-depth analysis of supply and sales channels, including upstream and downstream fundamentals, we present a complete market ecosystem.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Acquire This Reports: -

https://introspectivemarketresearch.com/checkout/?user=1&_sid=15847

About us:

Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyse extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

Contact us:

Introspective Market Research

3001 S King Drive,

Chicago, Illinois

60616 USA

Ph no: +1-773-382-1047

Email: sales@introspectivemarketresearch.com

[drarchitpandit]

How does Dr. Archit Pandit's expertise as a specialized surgeon for appendix cancer in Gurgaon translate into his focus on thoracic and gastro-esophageal surgeries within the realm of surgical oncology?

Dr. Archit Pandit, a specialized surgeon in Gurgaon, focuses on thoracic and gastro-esophageal surgeries, showcasing expertise in the realm of surgical oncology. Recognized as the Best Outgoing Surgeon in 2008 by Rajiv Gandhi University of Health Sciences, Karnataka, Dr. Pandit received extensive training at the Department of Surgical Oncology, BRAIRCH, All India Institute of Medical Sciences. With an 8-year academic experience in surgical oncology following MS (General Surgery), he has served as an Associate Director at the Department of Surgical Oncology at MAX INSTITUTE OF CANCER CARE and presently holds the position of Director at the Department of Surgical Oncology at Sanar International Hospital, Gurugram. Dr. Pandit excels in treating thoracic and gastro-esophageal malignancies, emphasizing minimal access oncology surgeries. Notable accolades include a Video Award in 2013 at the Indian Cancer Congress and Best Video Award at ACOS (Asian Clinical Oncology Society) in 2016, showcasing his dedication and skill in this field. His primary focus in clinical research has been on esophageal cancers, and he has numerous publications in esteemed international and national journals. Furthermore, he completed a one-year fellowship in laparoscopic and robotic oncology during his tenure as a Senior Research Associate at A.I.I.M.S.

[cancer-researcher]

International Conference on Oncology and Cancer Research Conference Next Conferences starts in the 21th Edition of the Oncology Summit | 24-26 June 2024 | San Francisco, United States, International Conference on Oncology and Cancer Research Conference organized by Pencis group.

Award Nomination link: https://x-i.me/oan

[gibrankhurshid]

Dr. Gibran Khurshid - A Trailblazer in Ophthalmology and Ocular Oncology

Dr. Gibran Khurshid's journey into the field of ophthalmology began in Ireland, where he completed his residency in 2004. During this time, he also pursued a Master of Medical Sciences degree with honors from the National University of Ireland. His passion for learning and advancing his skills led him to undertake a Pediatric and Adult retina fellowship at Queen’s Medical Centre, Nottingham, United Kingdom, before acquiring another fellowship in Advanced Retina surgery and Ocular Oncology from the prestigious Royal Liverpool University and Clatterbridge Cancer Centre, United Kingdom. Despite his international training, Dr. Khurshid is not a Canadian citizen or permanent resident but a national of the United States.

In 2014, Dr. Khurshid joined the University of Florida (UF), shortly after his promotion to Clinical Associate Professor at the University of Texas Medical Branch. He began at UF as a Clinical Assistant Professor but quickly rose to the rank of Clinical Associate Professor by 2017. Throughout his tenure at UF, Dr. Khurshid has worked tirelessly to enhance his clinical, educational, and research portfolios. His contributions in these fields have impacted not only his patients and the Department of Ophthalmology at UF but the ophthalmology community as a whole through collaborative research efforts and worldwide philanthropy.

As a director of the retina and ocular oncology service, Dr. Gibran Khurshid brings a patient-focused approach to the team, emphasizing customer service and patient satisfaction without compromising clinical excellence. Under his supervision, the retina service at UF has tripled from a lone retina surgeon to a service boasting three full-time retina faculty with a fellowship program. This feat of growth aligns with Dr. Khurshid's belief in providing exemplary patient care as the service ranks as the top revenue-generating service in the department.

In addition to leading the retina service, Dr. Khurshid showcases the most diverse surgical skills in the department. His surgical and clinical prowess has earned him referrals from exceptionally challenging patients around the country, as detailed in section 8 of his clinical portfolio. Since his promotion, he has founded the internationally recognized “Center of Artificial Vision” at UF, focusing on restoring vision in blind patients.

Dr. Khurshid is one of only thirteen surgeons in the nation who implants the Argus® II device, also known as a “bionic eye.” This innovative surgical procedure has attracted surgeons from around the world to UF for training. Patients across the U.S. are also referred to UF to receive this groundbreaking device, further raising UF’s national prominence.

In recent years, Dr. Khurshid began a clinical trial for the implantation of the Artisan lens, a new type of lens placed inside the eye to treat rare lens disorders. This lens is the only choice for patients in which the eye loses its natural support for the lens. Dr. Khurshid is the sole surgeon performing this surgery in the region.

Currently, Dr. Khurshid is collaborating with the Applied Genetic Therapies Corporation to bring unique genetic therapy to treat blind patients with rare inherited retinal conditions at UF. These treatments, like the Argus® II device, involve complex surgical procedures designed to restore visual function and meet the needs of patients with rare, blinding conditions. Once these treatments are successfully implemented, they will offer hope to patients previously deemed irreversibly blind. For his achievements in artificial vision and genetic therapies, Dr. Khurshid received the “Best Doctors in America Award” in 2019 and 2020 by the American Health Council.

Beyond his work in artificial vision, Gibran Syed Khurshid established the ocular oncology service at UF. As the only ocular oncologist at UF Gainesville and Jacksonville, he ensures that his patients have access to the latest modalities in vision- and life-saving therapies. Moreover, Dr. Khurshid successfully undertook the task of arranging radiation plaque therapy for patients with intraocular tumors, which required extensive interdisciplinary coordination. He offers unique, state-of-the-art, targeted proton radiation therapy for eye cancers. In addition, he has incorporated gene expression profiling of the eye melanoma to offer customized treatments to patients and provide more predictive survival analysis.

Conventionally, ocular melanoma is treated with either removing the eye or external beam radiation. However, Dr. Khurshid liaises with providers in general oncology, radiation oncology, and genetics to develop an individualized treatment plan that best meets the patient's needs. He has developed UF into a hub for clinical trials and research in ocular oncology by developing reputable collaborations with academic centers worldwide. He is one of three surgeons in the Southeast to offer iodine radiation and brachytherapy treatment. Dr. Gibran Khurshid has also developed new surgical procedures to excise melanomas from the

A keen clinician, educator, researcher, innovator, and leader, Dr. Khurshid is dedicated to enhancing the care of his patients and paving a brighter future for the next generation of eye care professionals. His commitment to excellence in all aspects of patient care continues to be demonstrated through his tireless pursuit of clinical excellence, research collaboration, and innovation.

Dr. Khurshid continues to shape the landscape of ophthalmology through his research, teaching, and leadership. His exceptional skills have allowed him to take on challenging cases with remarkable success, making him one of the leading ophthalmologists in the country. His exemplary work has been recognized by numerous awards and honors, including the prestigious American Health Council’s “Best Doctors in America Award” for 2019 and 2020. His commitment to delivering the highest quality of patient care is evident in his achievements thus far, and will continue to lead the field of ophthalmology into a brighter future.

From his innovative research and clinical trials to his passion for excellent patient service, Dr. Gibran Khurshid's journey is one of inspiration and exemplary standards in ophthalmology. As he looks towards the future, there isno doubt that he will continue to provide outstanding care and innovation for the benefit of his patients. Dr. Khurshid's success is a testament to the high standards of patient service, excellence in clinical care, and dedication to innovation that he embodies. His unique contributions continue to be an inspiration to aspiring ophthalmologists and medical professionals alike.

[evoldir]

Fwd: Postdoc: FredHutchinsonCenter_Washington.ComputationalBiology

Begin forwarded message: > From: evoldir@evol.biology.mcmaster.ca > Subject: Postdoc: FredHutchinsonCenter_Washington.ComputationalBiology > Date: 26 August 2023 at 07:44:02 BST > To: rdmpage@gmail.com > > > > Mahan Postdoctoral Fellowship > > The Herbold Computational Biology Program of the Fred Hutchinson Cancer > Center in Seattle, Washington invites applications for the Mahan > postdoctoral fellowship. The fellowship will provide an exceptional > individual with an early start on their career as an independent scientist > by providing a 21-month stipend to pursue their proposed research project > in the laboratory of a Fred Hutch Computational Biologist mentor. > > Faculty of any discipline or rank from the Fred Hutch, UW, or any other > institute may be proposed as co-mentors. The project must be focused on a > topic of biological interest, must involve a computational or mathematical > component, and may include an experimental component. A laboratory trained > scientist may satisfy the computational and mathematical requirement by > including a training component in their proposal. Computationally strong > candidates may include a laboratory training component as well. The > research direction should reflect the interests and ideas of the > applicant, although the final research proposal may be jointly designed; > see Additional Information for more details on the application process > and for a list of potential mentors. > > Fred Hutchinson Cancer Center is an independent, nonprofit organization > providing adult cancer treatment and groundbreaking research focused on > cancer and infectious diseases. Based in Seattle, Fred Hutch is the only > National Cancer Institute-designated cancer center in Washington. > > With a track record of global leadership in bone marrow transplantation, > HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has > earned a reputation as one of the world’s leading cancer, infectious > disease and biomedical research centers. Fred Hutch operates eight > clinical care sites that provide medical oncology, infusion, radiation, > proton therapy and related services, and network affiliations with > hospitals in five states. Together, our fully integrated research and > clinical care teams seek to discover new cures to the world’s deadliest > diseases and make life beyond cancer a reality. > > At Fred Hutch we value collaboration, compassion, determination, > excellence, innovation, integrity and respect. These values are > grounded in and expressed through the principles of diversity, > equity and inclusion. Our mission is directly tied to the humanity, > dignity and inherent value of each employee, patient, community member > and supporter. Our commitment to learning across our differences and > similarities make us stronger. We seek employees who bring different and > innovative ways of seeing the world and solving problems. Fred Hutch is > in pursuit of becoming an anti-racist organization. We are committed to > ensuring that all candidates hired share our commitment to diversity, > anti-racism and inclusion. > > Please direct all questions to Ruby Mae San Pedro, Computational Biology > Research Administrator. > > Qualifications > > Ph.D. must have been awarded after June 2021 in a computational, > quantitative or biological discipline. Ph.D. must be awarded prior to the > start of the fellowship.  Applicants who have held faculty or scientific > staff positions are not eligible. Fred Hutch Internal applicants – > Start date at Fred Hutch must be within 12 months of the pre-application > deadline. > > Application Instructions > > Please apply at: https://ift.tt/h96fVYe > > > > Kendall Kochmer > Pronouns: He/Him > Recruiting Program Coordinator > Fred Hutchinson Cancer Center > O - 206-667-2612 > kkochmer@fredhutch.org > > kkochmer@fredhutch.org > > (to subscribe/unsubscribe the EvolDir send mail to > golding@mcmaster.ca

[gastro-delhi]

Cancer Surgeon in Delhi

Cancer Surgeon in Delhi

Dr. Neeraj Goel

MBBS, MS, MCh (GI Surgery), Fellow Minimal Access HPB Surgery, South Korea, Robotic Surgery, Italy, Advanced Laparoscopic Colorectal Surgery, Taiwan, Obesity Surgery, USA

Dr Neeraj Goel is the first GI Surgeon in the East Delhi & NCR to provide comprehensive GI surgical and GI Oncologic care. He is trained in GI Surgery from coveted GB Pant Hospital. He has also done his fellowship in HPB Surgery from South Korea. He performs all kind of laparoscopic GI surgical procedures. He is a trained Robotic Surgeon.

Professional Qualifications

Dr. Neeraj Goel started his medical professional journey from University College Medical Science. He did his post graduation (MS) from Hardinge Medical College. He has done his postdoctoral degree(MCh) in GI Surgery from GB Pant Hospital.

He is the first GI Surgeon In East Delhi & adjoining NCR to start full-fledged GI Surgical Services

At Pushpanjali Crosslay Hospital (Now Max Hospital). Presently he is working as Director & Senior Consultant in Dharamshila Narayana Superspciality Hospital, Delhi. He is the only surgeon in East Delhi and NCR and amongst few in Country to perform complex surgery of Cytoreduction with HIPEC (Hyperthermic Introperitoneal Chemotherapy) for disseminated peritoneal Cancers. He is performing full array of advanced Minimal Access GI and HPB Surgery. He has worked as Senior Consultant Max Super specially Hospitals.

Minimal Access HPB Surgery

He is a fellow of Minimal Access HPBS Surgery from Seoul National University Bundang Hospital, South Korea.

Robotic Surgery

He is a certified Robotic Surgeon trained at International School of Robotic Surgery, Italy.

Advanced Laparoscopic Colorectal Surgery: Taiwan

He is trained in Taiwan for the advanced laparoscopic Colorectal Surgeries.

Weight loss Central at University of Cincinnati - Ohio USA

He has been to Weight Loss Centre at the University of Cincinnati, Ohio USA for Bariatric Surgery (Weight Loss Surgery).

GB Pant Hospital - Delhi

He completed his postdoctoral degree (MCh) in Surgical Gastroenterology/GI Surgery from coveted GB Pant Hospital Delhi.

Rajiv Gandhi cancer institute & Research Center - Delhi

At Rajiv Gandhi institute, he was involved in management and research of abdominal cancer.

He has to his credit multiple Chapters in post graduate and graduate books. He has many publications in national and international journal.

Awards & Honors

1. Faculty at various National and State level Surgical Conferences

2. Poster presentation on “Neuroendocrine Tumors of the ampulla” at Asia Pacific Hepatopancreatobiliary Association Conference in Shanghai, China.

3. Presented Poster on “Neuroendocrine Tumors of the ampulla” at Annual Conference of IASG, BaA video, India

4. Video presentation on ”Laparoscopic Lateral Pancreatojejunostomy” at Annual Conference of IASG, Bangaluru, India

5. Poster Presentation on “Isolated extrahepatic bile duct injury after blunt trauma abdomen” at Annual Conference of IASG, Bhopal, India

6. Stood Second In the Surgery Quiz at the Annual Conference of Delhi State Chapter of ASI, (as a team event).

7. Presented following papers at the Annual Meeting of Oncology Group of Delhi (OGD).

8. Gastrointestinal Stromal Tumors and Imatinib and its effect on Blood Sugar control. Deltopectoral Flap for Head & Neck Malignancies.

9. Presented Paper on Gastrointestinal Stromal Tumors: Our Experience at Annual Conference of Delhi State Chapter Of ASI.

Contact Information:

Name: Gastro Delhi

Address: D-1, Hakikat Rai Rd, Block D, Adarsh Nagar, Delhi, 110033

Phone: +91–9667365169, +91–9599294453

Website: www.gastrodelhi.com

[drnandinihazarika]

Pediatric Oncologist in Delhi

Dr Nandini Hazarika - The Best Pediatric Oncologist in Delhi NCR

Cancer is a life-threatening disease that can strike anyone at any age, and children are no exception. Pediatric cancer is a term used to describe cancer in children and is a rare and complex disease that requires specialized care. If your child is diagnosed with cancer, it is important to seek out the best possible care. Delhi NCR has several world-class Pediatric Oncologists, and Dr Nandini Hazarika is one of the best.

Dr. Nandini Hazarika is a highly skilled and experienced Pediatric Oncologist who specializes in the treatment of children with cancer. With over 20+ years of experience in pediatric hematology and oncology, she has treated numerous children with various types of cancers. She is dedicated to providing the best possible care to her patients and their families, and her compassionate approach has made her one of the most sought-after Pediatric Oncologist in Delhi.

Dr. NandiniHazarika completed her medical education from the prestigious Prince Aly Khan Hospital, Mumbai, and then went on to pursue further training in Pediatric Hematology and Oncology from some of the most renowned institutes in the world. She has also been actively involved in clinical research and has published several papers in reputed national and international journals.

Dr. Nandini Hazarika's expertise lies in the treatment of Pediatric Brain tumors, hematological malignancies, Thalassemia, Aplastic Anemia, metabolic disorders, leukemia, and lymphomas. She is also proficient in providing supportive care to her patients, which includes managing chemotherapy-related side effects, pain management, and nutritional support.

Her commitment to excellence and patient-centered care has earned her numerous accolades and awards. She is a member of various national and international professional organizations and has served as a speaker and panelist at various conferences and seminars.

If you are looking for the Best Pediatric Oncologist in Delhi NCR, look no further than Dr Nandini Hazarika. With her expertise, experience, and compassionate approach, she is the ideal doctor to help your child fight cancer and lead a healthy life.

[jasonjaramillomd]

Maimonides Medical Center and SUNY Downstate Announce New Partnership

Since securing his MD from the University of New Mexico in 2005, Dr. Jason Jaramillo has been practicing in New York City and assisting with medical aid efforts overseas. He served as internal medicine categorical resident physician with Brooklyn’s award-winning Maimonides Medical Center for three years. Jason Jaramillo, MD, subsequently established his community private practice with enduring Maimonides Medical Center affiliation and hospital privileges.

In February 2023, Maimonides Health (the parent organization of the Maimonides Medical Center) announced a new hematology-oncology collaboration. The endeavor involves Downstate Health (a clinical partnership between SUNY Downstate Health Sciences University as well as the University Hospital at Downstate [UHD]) and its faculty physician practice, the University Physicians of Brooklyn (UPB).

The SUNY/UHD/UPB collaboration aims to improve cancer care for underserved patients in Central Brooklyn by furthering patient access to lifesaving care at the Maimonides Cancer Center while simultaneously drawing upon the vast research capabilities of Downstate Health. This high level of care is particularly important in Central Brooklyn’s East Flatbush, Farragut, and Rugby neighborhoods, where residents face a disproportionately high risk of common forms of treatable cancer.